Catalyst Biosciences, Inc. (NASDAQ:CBIO) went up to recover about 14.19% since recording its record low price of $6.2. The stock experienced -4.07% slump, arriving at $7.08 on 6/7/2019. During the day, the stock price traveled from $6.92 to $7.4. This company shares are 319.07% off its target price of $29.67 and the current market capitalization stands at $88.43M. The recent change has given its price a -17.85% deficit over SMA 50 and -72.98% deficit over its 52-week high. The stock witnessed -21.07% declines, -9.92% declines and -30.59% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found CBIO’s volatility during a week at 5.42% and during a month it has been found around 5.1%.

Catalyst Biosciences, Inc. (CBIO) Top Holders

Institutional investors currently hold around $58 million or 77.7% in CBIO stock. Look at its top three institutional owners: Nantahala Capital Management, Llc owns $6.78 million in Catalyst Biosciences, Inc., which represents roughly 7.67% of the company’s market cap and approximately 11.7% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 823,090 shares of the stock are valued at $5.83 million. The third largest holder is Dimensional Fund Advisors Lp, which currently holds $4.71 million worth of this stock and that ownership represents nearly 5.33% of its market capitalization.

Catalyst Biosciences, Inc. 13F Filings

At the end of March reporting period, 30 institutional holders increased their position in Catalyst Biosciences, Inc. (NASDAQ:CBIO) by some 1,920,380 shares, 33 decreased positions by 1,229,866 and 11 held positions by 5,072,179. That puts total institutional holdings at 8,222,425 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 176,768 shares while 9 institutional investors sold out their entire positions totaling 563,678 shares.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Insider Trades

Multiple company employees have indulged in significant insider trading. Catalyst Biosciences, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Richard John P has acquired 1,000 shares of Catalyst Biosciences, Inc. (CBIO) in the trading session dated May. 24, 2019. These shares are worth $8,030 and were traded at $8.03 each. The SEC filing shows that Levy Howard performed a sale of 173 shares. The Chief Medical Officer disposed these shares by way of transaction on Nov. 16, 2018. The company’s shares were given away at $11 per share worth to an income of some $1,903 to the account of Levy Howard.

, Flynn James E, sold 71,778 common shares of Catalyst Biosciences, Inc. (CBIO) in the open market. In a transaction dated Mar. 08, 2018, the shares were put up for sale at an average price of $30.53, raking in a sum of $2,191,382. After this sale, 1,113,222 common shares of CBIO are directly owned by the insider, with total stake valued at $7,881,612.

In the transaction dated Mar. 08, 2018, a great number of shares sold came courtesy the ; Flynn James E disposed a total of 71,778 shares at an average price of $30.53, amounting to approximately $2,191,382. The insider now directly owns 1,113,222 shares worth $7,881,612.

Catalyst Biosciences, Inc. (CBIO) Analyst Guide

Several analysts have released their opinion on Catalyst Biosciences, Inc. (NASDAQ:CBIO), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.75 average brokerage recommendation [T1].